DOT1L was detected in immersion fixed paraffin-embedded sections of human lung using Human DOT1L Monoclonal Antibody (Catalog # MAB6546) at 15 µg/mL overnight at 4 °C. Before incubation with the primary antibody, ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Sterile PBS to a final concentration of 0.5 mg/mL.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for DOT1L Antibody (653613) [Unconjugated]
DOT1-like, histone H3 methyltransferase (S. cerevisiae)
KMT4H3 lysine-79 specific
Lysine N-methyltransferase 4
(mammalian counterpart of yeast Dot1) is a 1537 amino acid (aa), 165 kDa
(predicted) nuclear non-SET domain histone H3K79 methyltransferase. It is
involved in developmental gene transcription and maintenance of chromatin
structure, and may promote mixed lineage leukemia. Within the sequence used as
an immunogen, human DOT1L shares 97% and 94% aa identity with mouse and rat
DOT1L, respectively. Two human isoforms affect this region: a 1467 aa form has
an alternate start site at aa 71, while a 1513 aa form lacks aa 89-112. A third
isoform of 1739 aa has a 202 aa C-terminal extension.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our DOT1L Antibody (653613) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.